Cantor Fitzgerald reaffirmed its Overweight rating on Neurocrine Biosciences stock (NASDAQ:NBIX) with a consistent price target of $170.00. Currently trading at $150.51, the stock has shown strong ...
Several analysts raised the price target on Fiserv, Inc. (NYSE:FI) following fourth-quarter 2024 results reported on Wednesday. The company reported revenue of $5.25 billion, beating the analyst ...